Alcon (ALCN) Q3 2026 Earnings Report

The call was broadly positive. Alcon delivered 5% quarterly sales growth, 6% year-to-date growth, 15% core EPS growth, strong free cash flow and meaningful capital returns, while reporting momentum in equipment, contact lenses, ocular health and new product launches. The company also highlighted a broad innovation pipeline, the Neurotech acquisition and continued efficiency initiatives. The main negatives were competitive pressure in U.S. premium IOLs, softer international contact lens conditions, eye care markets at the low end of expectations, narrowed 2026 profitability guidance and several identified 2027 headwinds.

For 2026, Alcon expects sales growth of approximately 6%, core operating margin expansion of 100 to 150 basis points, and core diluted EPS growth of 12% to 14%, assuming aggregate eye care markets grew 3% for the year, exchange rates as of the end of October hold through year-end, and U.S. import tariff rates of approximately 10% to 12.5% remain in effect through year-end. For 2027, the base case assumes current market trends persist, with another year of above-market sales growth, Neurotech adding approximately 75 to 100 basis points to the top line, and roughly 150 to 200 basis points of gross operating leverage before the $60 million in tariff refunds, a $15 million milestone payment, incremental inflation related to memory and resins, and near-term pressure from the Neurotech acquisition; Alcon continues to expect margin improvement in 2027 and will issue formal guidance in February. The long-term 6% to 8% constant currency growth guide remains in place, but Alcon expects to be at the low end of that guide.